Ibalizumab

CHEBI:CHEBI_752712

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2043322
generic_name
Ibalizumab
pharm_class
HIV 1 Post-attachment Fusion Inhibitors [MoA]
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
active_ingredient_strength
150 mg/mL
route
INTRAVENOUS
marketing_start_date
20180420
marketing_category
DRUG FOR FURTHER PROCESSING
nui
N0000193807
pharm_class_cs
Antibodies, Monoclonal, Humanized [CS]
package_marketing_start_date
22-FEB-22
labeler_name
WuXi Biologics Co., Ltd.
manufacturer_name
Theratechnologies Inc.
product_ndc
71124-0024
spl_id
d8ce3c2c-2ca9-98d7-e053-2995a90ab83f
active_ingredient_name
IBALIZUMAB
package_ndc
71124-0024-0
package_description
1 SOLUTION in 1 VIAL (71124-0024-0)
brand_name
TROGARZO
brand_name_base
TROGARZO
application_number
BLA761065
unii
LT369U66CE
spl_set_id
c548ad82-9d1f-4d16-95b6-4e6106badf43
pharm_class_epc
Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC]
pharm_class_moa
HIV 1 Post-attachment Fusion Inhibitors [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class